← Full bleeding on HRT algorithm
Reasoning GP · Algorithm · 1-page summary

Unscheduled bleeding on HRT

For: women on systemic HRT (sequential, continuous combined or tibolone) with bleeding outside the expected pattern. Not for: postmenopausal bleeding off HRT (NICE NG12 route, block 2) or bleeding in pregnancy (early-pregnancy pathway). Use the local referral route.
Reviewed October 2026 · next review April 2027
BMS joint guideline 2024NICE NG23NG12MHRACoSRH
Core rule: HRT use does not protect against endometrial cancer. Bleeding outside the expected pattern, or any bleeding in a high-risk woman, needs a scan or referral — never reassure indefinitely.

0Stop — call 999 now — or same-day emergency assessment

  • Haemodynamic instability, or very heavy bleeding with collapse, syncope or cardiovascular compromise → 999
  • Positive pregnancy test with pain, bleeding, syncope, shoulder-tip pain or peritoneal signs → Same-day ectopic pathway; unstable → 999
  • Fever, pelvic pain or offensive discharge (esp. after IUS or instrumentation) → Same-day gynaecology; septic or unstable → 999
  • Symptomatic severe anaemia, severe pelvic pain, torsion or acute abdomen → Same-day. Check observations, pregnancy test (HRT is not contraception), FBC if heavy, anticoagulants.

1Triage by BMS risk and timing — count risk factors first

FindingAction
1 major / 3 minorSuspected-cancer pathway, whatever the timing
2 minorUrgent TVUS ≤6 weeks
Heavy / prolonged
Late or new
Low risk, earlyAdjust HRT; review at 3 months

Heavy (at any time): >7 days, flooding, clots, most days ≥4 weeks. Late: first bleed >6 months after starting or >3 months after a change, after amenorrhoea on ccHRT, or a changed pattern. Low risk, early: no major, ≤1 minor, not heavy, within those windows.

Major: BMI ≥40 · Lynch/Cowden · oestrogen-only >6 months with a uterus · tricycling >12 months · sequential >5 years started at ≥45 · inadequate progestogen ≥12 months. Minor: BMI 30–39 · oestrogen-only 3–6 months · tricycling 6–12 months · inadequate progestogen 6–12 months · disproportionate progestogen >12 months · expired 52 mg LNG-IUS · PCOS · diabetes.

2Screen — one row is enough

  • Postmenopausal bleeding not due to HRT timing: ≥55 → Suspected-cancer pathway; under 55 consider one (NG12).
  • Suspicious cervix → Suspected-cancer pathway, not waiting for cytology. Persistent post-coital bleeding, normal cervix → local gynaecology pathway.
  • Ascites or pelvic/abdominal mass not obviously fibroids → Suspected-cancer pathway, without waiting for CA-125. Ovarian-type symptoms aged 40+ → CA-125 (age-specific threshold) → urgent ultrasound.
  • Any bleeding on tamoxifen → Suspected-cancer pathway.

3Assess

☐ HRT type, progestogen and days, duration, last change, adherence  ☐ Timing vs progestogen phase, volume, post-coital  ☐ BMI, abdomen, speculum, bimanual  ☐ Screening status, tamoxifen. A smear is not a diagnostic test.

4Classify

  • Expected — sequential: withdrawal bleed at the end of the progestogen phase, up to 7 days. ccHRT: spotting in the first 6 months or 3 months after a change.
  • TVUS reassuring — ≤4 mm on ccHRT or ≤7 mm on sequential, fully seen and uniform → optimise HRT and review.
  • TVUS abnormal — above threshold or incomplete view → Suspected-cancer pathway endometrial assessment. Polyp or focal lesion → gynaecology hysteroscopy.
  • Atrophic vaginitis — pale, dry mucosa → vaginal oestrogen; new unexplained bleeding still needs assessment.
  • Uncertain — say so; do not label it "HRT bleeding". Scan or refer, with a named review date.

5Treat today — low risk only

  • Adherence and administration first; check the progestogen dose and days are adequate.
  • Sequential: at least 10 days/month norethisterone or MPA, or 12 days micronised progesterone. Consider reducing oestrogen or an alternative progestogen.
  • Consider a 52 mg LNG-IUS (prescribe by brand; change at 5 years for endometrial protection). Vaginal oestrogen for atrophy.
  • Sequential started after 45: consider switching to continuous combined after 5 years or by age 54. Doses: NICE/SPC, BNF, local formulary.

6Refer routinely

  • Persistent or recurrent bleeding despite a normal TVUS → gynaecology (usually hysteroscopy).
  • Heavy breakthrough bleeding on sequential HRT despite optimisation → gynaecology.
  • Regimen review, progestogen intolerance, pipelle → community gynaecology or menopause clinic.

7Never reassure by

  • "It's the HRT" beyond 6 months, or 3 months after a change.
  • A thin endometrium that was not fully seen.
  • A normal pipelle when bleeding continues.
  • Atrophy on examination or vaginal oestrogen use.
  • A normal screening smear.
  • Repeated HRT adjustment with no review date.

8Safety-net — say it, then document it

999 “Call 999 if you faint or collapse, or the bleeding is very heavy and you feel dizzy or unwell.” Same day: “Contact us today for severe pelvic pain, fever or smelly discharge, or a positive pregnancy test with pain or bleeding.” Back for a scan: “Tell us if the bleeding becomes heavy, lasts over 7 days, happens most days for 4 weeks, or has not settled when we review you at 3 months.”

Remote: book face to face — do not attribute bleeding to HRT, atrophy or the cervix without examination and investigation.

✓Safe to leave primary care only if — all five, documented

No block 0 or 2 row applies BMS major and minor factors counted Pattern judged against HRT type and timing Cervix examined; TVUS or adjustment plan set Review at 3 months booked; safety-net given
Summary of the full Reasoning GP bleeding on HRT algorithm, which holds the detail, formulations, pathology management and evidence. Sources: BMS/RCOG/BGCS/BSGE/CoSRH/RCGP/GIRFT unscheduled bleeding on HRT (2024); NICE NG23; NICE NG12 (updated April 2026); MHRA; CoSRH. Clinical reference — follow local referral pathways and check doses: NICE/SPC, BNF.